GTBP
Income statement / Annual
Last year (2025), GT Biopharma Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, GT Biopharma Inc's net income was -$28.35 M.
See GT Biopharma Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$4.00 K
|
$7.00 K
|
$2.00 K
|
$1.00 K
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$4.00 K
|
-$7.00 K
|
-$2.00 K
|
-$1.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$3.47 M
|
$5.80 M
|
$6.47 M
|
$8.81 M
|
$9.59 M
|
$485.00 K
|
$1.67 M
|
$9.07 M
|
$1.07 M
|
$975.00 K
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$47.92 M
|
$6.28 M
|
$0.00
|
$12.49 M
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$8.95 M
|
$8.57 M
|
$7.11 M
|
$12.45 M
|
$47.92 M
|
$6.28 M
|
$9.79 M
|
$12.49 M
|
$134.50 M
|
$8.40 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$12.42 M
|
$14.36 M
|
$13.58 M
|
$21.26 M
|
$57.52 M
|
$6.76 M
|
$11.45 M
|
$21.55 M
|
$135.57 M
|
$9.37 M
|
| Cost And Expenses |
$12.42 M
|
$14.36 M
|
$13.58 M
|
$21.26 M
|
$57.52 M
|
$6.76 M
|
$11.46 M
|
$21.55 M
|
$135.57 M
|
$9.37 M
|
| Interest Income |
$123.00 K
|
$402.00 K
|
$780.00 K
|
$292.00 K
|
$38.00 K
|
$3.32 K
|
$2.13 K
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$127.00 K
|
$0.00
|
$213.00 K
|
$8.00 K
|
$718.00 K
|
$3.32 M
|
$2.13 M
|
$9.12 M
|
$8.60 M
|
$6.56 M
|
| Depreciation & Amortization |
$0.00
|
$0.00
|
$13.58 M
|
$0.00
|
$0.00
|
$4.00 K
|
$4.00 K
|
$7.00 K
|
$2.00 K
|
$1.00 K
|
| EBITDA |
-$34.32 M |
-$13.16 M |
$5.98 M |
-$20.97 M |
-$57.48 M |
-$24.97 M |
-$36.52 M |
-$250.06 M |
-$135.57 M |
-$9.37 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$15.93 M
|
$1.20 M
|
$5.98 M
|
$373.00 K
|
-$498.00 K
|
-$21.53 M
|
-$27.19 M
|
-$9.12 M
|
-$8.60 M
|
$19.14 M
|
| Income Before Tax |
-$28.35 M
|
-$13.16 M
|
-$7.60 M
|
-$20.88 M
|
-$58.01 M
|
-$28.30 M
|
-$38.65 M
|
-$259.19 M
|
-$144.17 M
|
$9.77 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$28.35 M
|
-$13.16 M
|
-$7.60 M
|
-$20.88 M
|
-$58.01 M
|
-$28.30 M
|
-$38.65 M
|
-$259.19 M
|
-$144.17 M
|
$9.77 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-6.25 |
-6.94 |
-5.64 |
-0.66 |
-2.06 |
-6.45 |
-11.42 |
-87.7 |
-145.22 |
61200 |
| EPS Diluted |
-6.25 |
-6.94 |
-5.64 |
-0.66 |
-2.06 |
-6.45 |
-11.42 |
-87.7 |
-145.22 |
61200 |
| Weighted Average Shares Out |
$5.51 M
|
$1.90 M
|
$1.35 M
|
$31.87 M
|
$28.16 M
|
$4.39 M
|
$3.39 M
|
$2.96 M
|
$986.42 K
|
$159.66
|
| Weighted Average Shares Out Diluted |
$5.51 M
|
$1.90 M
|
$1.35 M
|
$31.87 M
|
$28.16 M
|
$4.39 M
|
$3.39 M
|
$2.96 M
|
$986.42 K
|
$159.66
|
| Link |
|
|
|
|
|
|
|
|
|
|
